195 related articles for article (PubMed ID: 33782049)
61. Is Barrett's metaplasia the source of adenocarcinomas of the cardia?
Clark GW; Smyrk TC; Burdiles P; Hoeft SF; Peters JH; Kiyabu M; Hinder RA; Bremner CG; DeMeester TR
Arch Surg; 1994 Jun; 129(6):609-14. PubMed ID: 8204035
[TBL] [Abstract][Full Text] [Related]
62. Surgical treatment of Barrett's esophagus: 1980-2003.
Csendes A
World J Surg; 2004 Mar; 28(3):225-31. PubMed ID: 14961203
[TBL] [Abstract][Full Text] [Related]
63. Management of Nodular Neoplasia in Barrett's Esophagus: Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection.
Belghazi K; Bergman JJGHM; Pouw RE
Gastrointest Endosc Clin N Am; 2017 Jul; 27(3):461-470. PubMed ID: 28577767
[TBL] [Abstract][Full Text] [Related]
64. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
65. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.
O'Connor JB; Falk GW; Richter JE
Am J Gastroenterol; 1999 Aug; 94(8):2037-42. PubMed ID: 10445525
[TBL] [Abstract][Full Text] [Related]
66. [Barrett carcinoma--diagnosis, screening, surveillance, endoscopic treatment, prevention].
Peitz U; Malfertheiner P
Z Gastroenterol; 2007 Dec; 45(12):1264-72. PubMed ID: 18080229
[TBL] [Abstract][Full Text] [Related]
67. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter study.
van Vilsteren FG; Alvarez Herrero L; Pouw RE; Schrijnders D; Sondermeijer CM; Bisschops R; Esteban JM; Meining A; Neuhaus H; Parra-Blanco A; Pech O; Ragunath K; Rembacken B; Schenk BE; Visser M; ten Kate FJ; Meijer SL; Reitsma JB; Weusten BL; Schoon EJ; Bergman JJ
Endoscopy; 2013 Jul; 45(7):516-25. PubMed ID: 23580412
[TBL] [Abstract][Full Text] [Related]
68. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
[TBL] [Abstract][Full Text] [Related]
69. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
70. Potential application of p53 as an intermediate biomarker in Barrett's esophagus.
Jones DR; Davidson AG; Summers CL; Murray GF; Quinlan DC
Ann Thorac Surg; 1994 Mar; 57(3):598-603. PubMed ID: 8147627
[TBL] [Abstract][Full Text] [Related]
71. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
[TBL] [Abstract][Full Text] [Related]
72. In Barrett's epithelial cells, weakly acidic bile salt solutions cause oxidative DNA damage with response and repair mediated by p38.
Huo X; Dunbar KB; Zhang X; Zhang Q; Spechler SJ; Souza RF
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G464-G478. PubMed ID: 31984785
[TBL] [Abstract][Full Text] [Related]
73. Histopathology of Barrett's esophagus after ablation and endoscopic mucosal resection therapy.
Odze RD; Lauwers GY
Endoscopy; 2008 Dec; 40(12):1008-15. PubMed ID: 19065484
[TBL] [Abstract][Full Text] [Related]
74. Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus.
Chak A; Buttar NS; Foster NR; Seisler DK; Marcon NE; Schoen R; Cruz-Correa MR; Falk GW; Sharma P; Hur C; Katzka DA; Rodriguez LM; Richmond E; Sharma AN; Smyrk TC; Mandrekar SJ; Limburg PJ;
Clin Gastroenterol Hepatol; 2015 Apr; 13(4):665-72.e1-4. PubMed ID: 25218668
[TBL] [Abstract][Full Text] [Related]
75. Probe-based confocal laser endomicroscopy compared with standard four-quadrant biopsy for evaluation of neoplasia in Barrett's esophagus.
Bajbouj M; Vieth M; Rösch T; Miehlke S; Becker V; Anders M; Pohl H; Madisch A; Schuster T; Schmid RM; Meining A
Endoscopy; 2010 Jun; 42(6):435-40. PubMed ID: 20506064
[TBL] [Abstract][Full Text] [Related]
76. Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.
Yachimski P; Mino-Kenudson M; Sherwood ME; Puricelli WP; Nishioka NS; Lauwers GY
Virchows Arch; 2011 Dec; 459(6):581-6. PubMed ID: 22081106
[TBL] [Abstract][Full Text] [Related]
77. Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus.
Asthana N; Mandich D; Ligato S
Am J Surg Pathol; 2008 Oct; 32(10):1581-5. PubMed ID: 18724240
[TBL] [Abstract][Full Text] [Related]
78. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
79. [Barrett's esophagus carcinoma].
Messmann H
Praxis (Bern 1994); 2006 Jun; 95(25-26):1029-35. PubMed ID: 16836063
[TBL] [Abstract][Full Text] [Related]
80. [Radio frequency ablation of Barrett's esophagus--can the risk of esophageal adenocarcinoma be reduced?].
Salminen P; Räsänen J; Ristimäki A; Saarnio J; Heikkinen M; Laine S; Koivisto T; Färkkilä M
Duodecim; 2014; 130(6):557-64. PubMed ID: 24724454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
